Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats

Diabetes, Obesity and Metabolism

Volumn 5, Issue 4, 2003, Pages 234-243

  Hockings, Paul D ^a   Changani, K K ^a   Saeed, N ^a   Reid, D G ^a   Birmingham, J ^a   O'Brien, P ^a   Osborne, J ^a   Toseland, C N ^a   Buckingham, R E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

EMCL; Fat; Hepatic; IMCL; Liver; MRI; MRS; PPAR; Rat; Rosiglitazone; Steatosis; Zucker

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CELL VACUOLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; FATTY LIVER; HEPATOMEGALY; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIVER SIZE; LIVER WEIGHT; MALE; MUSCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; RAT STRAIN; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0038759221     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00268.x     Document Type: Article

References (58)

1. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.
2. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
3. Phillips DI, Caddy S, Ilic V et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996; 45: 947-950.
4. Forouhi NG, Jenkinson G, Thomas EL et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 1999; 42: 932-935.
5. Jacob S, Machann J, Rett K et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999; 48: 1113-1119.
6. Perseghin G, Scifo P, De Cobelli F et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48: 1600-1606.
7. Krssak M, Falk PK, Dresner A et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999; 42: 113-116.
8. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501.
9. Diehl AM. Nonalcoholic steatohepatitis. Seminars Liver Dis 1999; 19: 221-229.
10. Diehl AM. Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis. Alcoholism: Clin Exp Res 2001; 25: 8s-14s.
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
13. Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327.
14. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
15. Jowsey IR, Murdock PR, Moore GB, Murphy GJ, Smith SA, Hayes JD. Prostaglandin D2 synthase enzymes and PPAR-gamma are co-expressed in mouse 3T3-L1 adipocytes and human tissues. Prostaglandins Other Lipid Med 2003; 70: 267-284.
16. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
17. Carey DG, Cowin GJ, Galloway GJ et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obesity Res 2002; 10: 1008-1015.
18. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
19. Virtanen KA, Hallsten K, Parkkola R et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283-290.
20. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
21. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-315.
22. Hallsten K, Virtanen KA, Lonnqvist F et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-3485.
23. Wehmeier KR, Neuschwander-Tetri BA, Brunt EM et al. Rosiglitazone lowers aminotransferases in nonalcoholic steatohepatitis. Abstracts of ENDO 2002 Meeting 2002, OR11-5
24. Zarjevski N, Doyle P, Jeanrenaud B. Muscle insulin resistance may not be a primary etiological factor in the genetically obese fa/fa rat. Endocrinology 1992; 130: 1564-1570.
25. McCaleb ML, Sredy J. Metabolic abnormalities of the hyperglycemic obese Zucker rat. Metabolism 1992; 41: 522-525.
26. King PA, Horton ED, Hirshman MF, Horton ES. Insulin resistance in obese Zucker rat (fa/fa) skeletal muscle is associated with a failure of glucose transporter translocation. J Clin Invest 1992; 90: 1568-1575.
27. Koteish A, Diehl AM. Animal models of steatosis. Seminars Liver Dis 2001; 21: 89-104.
28. Turcotte LP, Swenberger JR, Zavitz TM, Yee AJ. Increased fatty acid uptake and altered fatty acid metabolism in insulin-resistant muscle of obese Zucker rats. Diabetes 2001; 50: 1389-1396.
29. Lee JK, Dixon WT, Ling D, Levitt RG, Murphy Jr WA. Fatty infiltration of the liver: demonstration by proton spectroscopic imaging. Preliminary observations. Radiology 1984; 153: 195-201.
30. Longo R, Pollesello P, Ricci C et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-285.
31. Hazle JD, Narayana PA, Dunsford HA. In vivo NMR, biochemical, and histologic evaluation of alcohol-induced fatty liver in rat and a comparison with CCl4 hepatotoxicity. Magn Reson Med 1991; 19: 124-135.
32. Ling M, Brauer M. Ethanol-induced fatty liver in the rat examined by in vivo 1H chemical shift selective magnetic resonance imaging and localized spectroscopic methods. Magn Reson Imaging 1992; 10: 663-677.
33. Szczepaniak LS, Babcock EE, Schick F et al. Measurement of intracellular triglyceride stores by 1H spectroscopy: validation in vivo. Am J Physiol 1999; 276: e977-e989.
34. Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn Reson Med 1993; 29: 158-167.
35. Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med 1997; 37: 484-493.
36. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 1570-1576.
37. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker Fatty rat heart. Diabetes 2002; 51: 1110-1117.
38. Wilson SJ, Brereton IM, Hockings PD, Roffmann W, Doddrell DM. Respiratory triggered imaging with an optical displacement sensor. Magn Reson Imaging 1993; 11: 1027-1032.
39. Schwarz AJ, Leach MO. Implications of respiratory motion for the quantification of 2D MR spectroscopic imaging data in the abdomen. Physics Med Biol 2000; 45: 2105-2116.
40. Kimmich R, Hoepfel D. Volume selective multipulse spin echo spectroscopy. J Magn Reson 1987; 72: 379-384.
41. Hajnal JV, Saeed N, Soar EJ, Oatridge A, Young IR, Bydder GM. A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J Comput Assist Tomo 1995; 19: 289-296.
42. Delesse A. Procede mechanique pour determiner la compossition des roches. Annis Mines 1848; 13: 379-388.
43. Elias H, Hyde DM, Scheaffer RL. A Guide to Practical Stereology Basel: Karger, 1983.
44. Ibrahimi A, Teboul L, Gaillard D et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 1994; 46: 1070-1076.
45. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism: Clin Exp 1997; 46: 935-942.
46. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
47. Boden G, Jadali F, White J et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991; 88: 960-966.
48. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50: 1612-1617.
49. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991; 72: 96-107.
50. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993; 92: 91-98.
51. Roden M, Price TB, Perseghin G et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
52. Charles MA, Eschwege E, Thibult N et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997; 40: 1101-1106.
53. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
54. Ryysy L, Hakkinen AM, Goto T et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-758.
55. Mittelman SD, Van Citters GW, Kim SP et al. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 2000; 49: 2116-2125.
56. Hallsten K, Virtanen KA, Lonnqvist F et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-3485.
57. Eldershaw TP, Rattigan S, Cawthorne MA, Buckingham RE, Colquhoun EQ, Clark MG. Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. Horm Metab Res 1995; 27: 169-172.
58. Jucker BM, Schaeffer TR, Haimbach RE et al. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes 2002; 51: 2066-2073.